Findings indicate that cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) and intraoperative radiation therapy (IORT) significantly improves overall survival (63 months) and disease-free survival (87 months) for gastric cancer patients. Over one-third of participants experienced no postoperative complications, while those who did faced a median of just one complication, primarily grade II. The absence […]
Category: Cytoreductive Surgery & Peritoneum
Identification of Key Risk Factors for Postoperative Kidney Injury
A meta-analysis of seven studies involving 1,550 patients has pinpointed significant preoperative and intraoperative risk factors for acute kidney injury (AKI) after cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS + HIPEC). Preoperative factors include age, sex, BMI, and diabetes, while intraoperative factors include low systolic blood pressure and cisplatin use; however, mitomycin shows protective effects. Variations […]
Machine-learning model predicts postoperative infection risk after surgery
A machine-learning model, specifically the extreme gradient boost (XGBoost), was developed to predict postoperative infection following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with splenectomy. The model demonstrated excellent prediction accuracy, achieving an area under the curve (AUC) of 0.910 in preliminary testing and 0.823 in external validation. Data was analyzed from a cohort of 1,016 […]
Tumor-Stroma Ratio Accurately Predicts Peritoneal Metastasis in Gastric Cancer
Analysis reveals a strong correlation between tumor-stroma ratio (tsr) and peritoneal metastasis (pm) in gastric cancer patients. The study included 640 patients across several cohorts, establishing a diagnostic model integrating tsr with CA125, CA724, and Borrmann type. The model demonstrated robust predictive capabilities, achieving an area under the curve (AUC) of 0.85 in the training […]
Preoperative tumor markers predict surgical outcomes in peritoneal metastases
Clustering preoperative tumor marker patterns aids in predicting surgical outcomes for patients with peritoneal metastases. Among 138 with pseudomyxoma peritonei (pMP), two distinct clusters emerged—pMP cluster-1 had a 5-year overall survival rate of 77%, while pMP cluster-2 faced a significantly poorer prognosis of 36%. A similar pattern was observed in 213 colorectal peritoneal metastases patients, […]
Cytoreductive surgery improves survival in colorectal peritoneal metastases.
In patients with colorectal peritoneal metastases, cytoreductive surgery has shown significant survival benefits, regardless of the use of intraperitoneal chemotherapy. Despite recent challenges to the efficacy of intraperitoneal treatments, the comprehensive review indicates that surgical intervention remains a crucial component in managing this aggressive form of cancer. The study emphasizes a critical analysis of current […]
Cytoreductive surgery with HIPEC improves survival in CRC patients.
A systematic review and meta-analysis encompassing 14 studies reveal that colorectal cancer patients with peritoneal metastases experience enhanced overall survival (OS) and relapse-free survival (RFS) following cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC). Compared to control regimens, the CRS + HIPEC approach markedly improves these outcomes, shedding light on effective therapeutic strategies for […]
Surgical complications from CRS and HIPEC in cancer patients
A narrative review assessed complications linked to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients battling peritoneal metastasis. It cataloged categories of complications, including surgical, chemotherapy-related, and systemic issues, emphasizing the high morbidity associated with these interventions. The findings advocate for stringent patient selection, precise surgical techniques, and robust intraoperative care. Interdisciplinary collaboration is highlighted […]
Multisocietal consensus supports CRS and HIPEC for DMPM patients
A multisocietal consensus has endorsed cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for treating diffuse malignant peritoneal mesothelioma (DMPM). An expert panel, acknowledging the limited efficacy of systemic chemotherapy, strongly recommended this approach for a select subgroup of patients. Despite low evidence certainty, the panel emphasized the potential for improved survival outcomes with CRS-HIPEC, […]
Cytoreductive surgery enhances survival in colorectal cancer patients.
A bicentric analysis revealed that patients with colorectal cancer peritoneal metastases (crpm), particularly when isolated or with limited extraperitoneal metastases (epm), experience significantly improved median overall survival (58 months vs. 39 months) following cytoreductive surgery. The study involved 413 patients, demonstrating similar postoperative outcomes between those with and without epm. Notably, specific prognostic groups identified […]